India's Laurus Labs gains on Q1 profit surge

Laurus Labs

28/07/2025 06:24

** Laurus Labs LAUL.NS gains 5.5% to 883.50 rupees

** API maker reports eleven-fold surge in Q1 consol net profit, led by strong demand for its active ingredients for generic drugs and in contract manufacturing (CDMO) business

** EBITDA margins expand to 24.8% from year-ago 14.3%, which LAUL attributed to ramp-up in CDMO projects

** Goldman Sachs says CDMO business "going from strength to strength," citing the more-than-double jump in CDMO revenue

** Raises FY26-28 EPS estimates by 3%-22% to factor in faster topline growth; ups PT to 675 rupees from 600 rupees

** Stock rated "hold" on avg; median PT is 650 rupees, per data compiled by LSEG

** LAUL gains ~47% YTD

 (Reporting by Kashish Tandon in Bengaluru)

 ((Kashish.tandon@thomsonreuters.com))